Although the evidence for whether or not hyperprolactinemia and its magnitude are per se associated with increased breast cancer risk is lacking, clinicians should proactively monitor for hyperprolactinemia and breast cancer risk when prescribing prolactin-raising antipsychotics. This evidence concerns the gene PRL and hyperprolactinemia.